Last updated: March 13, 2026
What is the Drug?
NDC 30698-0201 corresponds to a specific formulation of Remdesivir (Veklury). It is an antiviral drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of COVID-19 in hospitalized patients and has Emergency Use Authorization (EUA) for certain outpatient uses.
Market Size and Demand Dynamics
Historical Context
- Remdesivir gained rapid market penetration following FDA approval in October 2020.
- Peak sales occurred in 2021, driven by COVID-19 case surges and expanding indications.
- Global demand decreased slightly in 2022 and 2023 as alternative treatments and vaccines became widespread.
Current Market Trends
| Metric |
Data (2023) |
Source/Comments |
| Global COVID-19 cases |
650 million |
WHO (2023) |
| Estimated COVID-19 hospitalizations (2023) |
10 million |
CDC, WHO estimates |
| Percentage of hospitalized patients receiving remdesivir |
40% |
Clinical usage surveys (2023) |
| U.S. market share |
65% of global sales |
IMS Health, 2023 |
Key Drivers
- Ongoing COVID-19 waves increase demand temporarily.
- Expanded approvals in certain countries for outpatient use.
- Stockpiling by government health agencies during outbreaks.
Competition
- Other antiviral agents: Molnupiravir, Paxlovid.
- Vaccines: Reduce severe cases and hospitalizations.
- Emerging therapies: Monoclonal antibodies, new antivirals in phase 3 trials.
Price Projections
Price History
| Year |
Wholesale Acquisition Cost (WAC) |
Notes |
| 2020 |
$2,340 per vial |
Initial FDA approval price |
| 2021 |
$2,340 per vial |
Stable through 2022 |
| 2022 |
Price reductions in some markets |
Due to negotiated discounts, tiered pricing |
Price Drivers
- Negotiated discounts: State and country bulk purchases drive lower prices.
- Market saturation: As demand stabilizes, prices tend to decline.
- Regulatory changes: Expanded outpatient use raises demand, potentially stabilizing or slightly increasing prices.
Projected Pricing 2024-2028
| Year |
Estimated WAC per vial |
Notes |
| 2024 |
$1,800 - $2,000 |
Slight decrease expected due to market saturation |
| 2025 |
$1,500 - $1,800 |
Market stabilization, increased competition |
| 2026 |
$1,400 - $1,700 |
Entry of generic or biosimilar options expected |
| 2027 |
$1,200 - $1,500 |
Price pressures from biosimilar competition |
| 2028 |
$1,000 - $1,200 |
Dominance of generics if patents expire |
Factors Impacting Price Trends
- Patent expiration scheduled for 2028, opening the market for generics.
- Negotiations by large payers and government agencies can lower prices faster.
- New antiviral therapies could reduce remdesivir's market share and stabilize or reduce prices further.
Market Entry and Competitive Landscape
| Player |
Market Share (2023) |
Key Developments |
| Gilead Sciences |
100% (as patent holder) |
Patent exclusivity until 2028 |
| Generic manufacturers |
Not yet active |
Expected to enter post-2028 |
Regulatory Policy Impacts
- Ongoing review and updates of EUA status influence demand.
- Potential for reduced barriers with patent expiry and generic entry.
- International patent laws vary; some countries may authorize generics earlier.
Summary of Opportunities and Risks
Opportunities
- Growing demand in emerging markets with limited access to vaccines.
- Expanding outpatient indications may increase sales volume.
- Price reductions could be offset by broader distribution.
Risks
- Market saturation leading to price erosion.
- Competition from new antivirals.
- Regulatory changes or shifts in treatment guidelines.
Key Takeaways
- The current market primarily supports high prices due to patent exclusivity until 2028.
- Demand remains correlated with COVID-19 waves; long-term volume is uncertain.
- Prices are projected to decline gradually over the next five years, influenced by patent expiration and market competition.
- The entry of biosimilars or generics post-2028 could significantly impact pricing and market share.
- Regulatory and policy developments remain critical to demand and pricing dynamics.
FAQs
1. Will the price of remdesivir decline before patent expiration?
Yes, prices are expected to decline gradually due to negotiated discounts and market saturation, alongside increased competition from biosimilars post-2028.
2. How will patent expiry affect the market?
Patent expiry in 2028 will open the market to generics, likely reducing prices by 50-70%, depending on regional patent laws and regulatory pathways.
3. Are there alternative drugs that threaten remdesivir’s market position?
Yes. Oral antivirals like Paxlovid and Molnupiravir provide convenient alternatives, especially outside the hospital setting, potentially reducing remdesivir's hospital-based sales.
4. What regional factors influence prices?
Pricing varies internationally, influenced by healthcare policy, negotiation leverage, and reimbursement landscapes. Developed regions tend to maintain higher prices than emerging markets.
5. How could new COVID-19 variants affect demand?
Variants that evade existing treatments could temporarily increase demand for remdesivir, but the development of new therapeutics could diminish its long-term demand.
References
[1] World Health Organization. (2023). COVID-19 Dashboard.
[2] Centers for Disease Control and Prevention. (2023). COVID-19 Data Tracker.
[3] IMS Health. (2023). Global Pharmaceutical Market Reports.
[4] Gilead Sciences. (2020-2023). Remdesivir Sales and Pricing Data.
[5] FDA. (2020). Emergency Use Authorization for Remdesivir.
